首页 › 慢性淋巴细胞白血病 › 密歇根州 › Detroit
Detroit MI 慢性淋巴细胞白血病临床试验
7项针对 慢性淋巴细胞白血病的研究正在 Detroit及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本(英文)
正在为研究招募参与者?将此页面置顶展示 — $99 / 30天 →
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
招募中1/2 期
- Karmanos Cancer Institute, Detroit
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
招募中观察性研究欢迎健康志愿者
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
招募中3 期
- Henry Ford Hospital, Detroit
- Henry Ford Health Saint John Hospital, Detroit
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
招募中3 期
- Karmanos Cancer Institute, Detroit
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
招募中2 期
- Karmanos Cancer Center, Detroit
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
招募中3 期
- Henry Ford Hospital /ID# 270973, Detroit
HPC Offered for PRESERVE Expansion
招募中观察性研究
- Henry Ford Health, Detroit
其他城市的 慢性淋巴细胞白血病试验
- Boston, MA31 项研究
- Columbus, OH28 项研究
- Durham, NC27 项研究
- Washington, DC22 项研究
- Seattle, WA20 项研究
- Rochester, MN18 项研究
- New York City, NY18 项研究
- Houston, TX17 项研究
- Baldwin Park, CA16 项研究
- Milwaukee, WI15 项研究
- Chicago, IL14 项研究
- Cincinnati, OH14 项研究
Detroit的其他研究
- 非小细胞肺癌44 项研究
- 乳腺癌33 项研究
- 癌症(所有类型)29 项研究
- 结直肠癌26 项研究
- 卵巢癌26 项研究
- 转移性癌症24 项研究
- 前列腺癌22 项研究
- 子宫内膜癌21 项研究
- 肺癌20 项研究
- 多发性骨髓瘤19 项研究
- 胃癌16 项研究
- 头颈鳞状细胞癌15 项研究
数据来自 ClinicalTrials.gov,检索日期:2026年10月6日。每项研究自行设定入选标准,由研究团队决定谁能参与。